The Nepal Stock Exchange (NEPSE) index dropped by 35.73 points on Tuesday, closing at 2,658.93. The decline represents a 1.32 ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

Darolutamide improved clinically relevant secondary end points of time to castration-resistant prostate cancer and subsequent systemic antineoplastic therapy versus placebo in all disease volume and ...

Using the COMPASS model, researchers project risk of cardiac late effects for survivors of pediatric ALL at age 50 years.

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

What this ultimately resulted in was the classification of four autism subgroups. The first two subgroups were noted for displaying high levels of verbal intelligence. One of them, however ...

Adding atezolizumab to standard adjuvant chemotherapy significantly delayed recurrence or death for individuals with stage ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Results showed not only a continued PFS benefit of nivolumab and relatlimab in key subgroups, but also superior OS and ORR rates, although Tawbi stressed the study was not adequately powered for ...